64th ASH Annual Meeting and Exposition: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Lymphoid Leukemias, ALL, clinical trials, adult, Translational Research, assays, genomics, bioinformatics, Combination therapy, Clinical Research, hematopoiesis, pediatric, Diseases, Therapies, Lymphoid Malignancies, computational biology, Myeloid Malignancies, Biological Processes, Technology and Procedures, Study Population, profiling, Human, Minimal Residual Disease , machine learning, omics technologies

New Orleans Theater C (Ernest N. Morial Convention Center)

Moderators:

Linde A. Miles, PhD, Cincinnati Children's Hospital Medical Center and Robert L. Bowman, PhD, University of Pennsylvania

Disclosures:

Bowman: Mission Bio: Honoraria, Speakers Bureau.

4:30 PM

943

Single-Cell Map of Childhood Acute Myeloid Leukaemia Using Variational Auto-Encoders

Alice Driessen^1,2^*, Susanne Unger³^*, An-phi Nguyen^1,2^*, Stefanie Kreutmair³^*, Chiara Alberti³^*, Aakriti Sethi³^*, Richard Aplenc, MD, PhD⁴, Michele S. Redell, MD PhD⁵, Maria Rodriguez Martinez¹^* and Burkhard Becher³^*

¹IBM Research Zürich, Zurich, Switzerland
²ETH Zürich, Zurich, Switzerland
³Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland
⁴Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA
⁵Baylor College of Medicine, Houston, TX

4:45 PM

944

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Alexandre Bazinet, MD¹, Tapan M. Kadia, MD², Nicholas Short, MD³, Gautam Borthakur, MD¹, Sa A Wang, MD⁴^*, Sanam Loghavi, MD⁵, Jeffrey L. Jorgensen, MD, PhD⁵^*, Keyur P. Patel, MBBS, PhD⁵, Courtney D. DiNardo, MD, MSCE¹, Naval Daver, MD¹, Yesid Alvarado, MD¹, Fadi Haddad, MD¹^*, Sherry A. Pierce, BSN, BA¹^*, Graciela M. Nogueras González, MPH⁶^*, Abhishek Maiti, MBBS⁷, Michael Andreeff, MD, PhD¹, Elias Jabbour, MD¹, Marina Konopleva, MD, PhD³, Xuelin Huang, PhD⁶^*, Hagop Kantarjian, MD⁸ and Farhad Ravandi, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, TX
⁵Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
⁸Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 PM

945

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Catia Patricia Simoes, MD¹^*, Sara Villar²^*, Beñat Ariceta, BSc³^*, Juan-José Garcés, PhD⁴, Leire Burgos⁵^*, Diego Alignani, PhD⁵^*, Sarvide Sarai⁶^*, David Martinez-Cuadron⁷^*, Juan Miguel Bergua Burgués⁸^*, Susana Vives, PhD⁹^*, Lorenzo Algarra¹⁰^*, Mar Tormo¹¹, Pilar Martinez Sanchez, MD¹²^*, Josefina Serrano¹³^*, Pilar Herrera¹⁴^*, Fernando Ramos¹⁵^*, Olga Salamero¹⁶^*, Esperanza Lavilla¹⁷^*, Cristina Gil¹⁸^*, Jose Luiz Lopez Lorenzo, MD¹⁹^*, María Belén Vidriales, MD²⁰^*, María Carmen Chillón Santos, PhD²¹^*, Jorge Labrador²²^*, José F. Falantes²³^*, Maria Jose Sayas²⁴^*, Rosa Ayala²⁵^*, Joaquín Martínez-López, MD, PhD²⁶^*, Ana Alfonso-Pierola, MD, PhD²⁷^*, María José Calasanz, PhD⁵^*, Felipe Prosper, MD²⁸^*, Jesús San-Miguel, MD, PhD²⁹, Miguel A. Sanz, MD³⁰, Pau Montesinos, PhD, MD³¹^* and Bruno Paiva³²^*

¹Clinica Universidad De Navarra, Centro De Investigacion Medica Aplicada (CIMA),, Pamplona, Spain
²Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, C-CUN, CIBER-ONC, Pamplona, Pamplona, Spain
³Hematological Diseases Laboratory, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, C-CUN, CIBER-ONC, Pamplona, Pamplona, Spain
⁴Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad De Navarra - Centro De Investigación Médica Aplicada, Pamplona, Spain
⁵Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain
⁶Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
⁷Hospital Universitario La Fe, Valencia, Valencia, Spain
⁸Hospital San Pedro de Alcántara, Cáceres, Spain
⁹ICO-Hospital Germans Trias i Pujol, Badalona, Spain
¹⁰Hospital Universitario General de Albacete, Albacete, Spain
¹¹Hospital Clínico Universitario de Valencia, Valencia, Spain
¹²Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid, Spain
¹³IMIBIC, Cordoba, Spain
¹⁴Hospital Universitario Ramón y Cajal, Madrid, Spain
¹⁵Department of Hematology, Hospital Universitario De LeóN and Instituto De Biomedicina (IBIOMED), Un, Leon, Spain
¹⁶Hospital Universitario Vall d'Hebrón, Barcelona, Barcelona, Spain
¹⁷Hospital Universitario Lucus Augusti, Lugo, Spain
¹⁸Hematology Department, Hospital General Universitario de Alicante, Alicante, Spain
¹⁹Fundación Jiménez Díaz, Madrid, Madrid, Spain
²⁰Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca, Salamanca, Spain
²¹Hematology Dept., Hospital Universitario de Salamanca, Spain, Salamanca, Spain
²²Hospital Universitario de Burgos, Burgos, Burgos, Spain
²³Hospital Universitario Virgen del Rocío, Sevilla, Spain
²⁴Hospital Universitario Dr. Peset, Valencia, Spain
²⁵Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain
²⁶Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
²⁷Department of Oncology-Hematology, Centro de Investigación Médica Aplicada (CIMA), Navarra university-IDISNA. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Clínica Universidad de Navarra, Pamplona, Spain
²⁸Department of Oncology-Hematology, Centro de Investigación Médica Aplicada (CIMA), Navarra university-IDISNA. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Clínica Universidad de Navarra, Pamplona, Navarra, Spain
²⁹Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
³⁰Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
³¹Hospital Politecnico Universitario La Fe, Valencia, Spain, Spain
³²Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain

5:15 PM

946

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Muharrem Muftuoglu, MD¹, Musa Yilmaz, MD², Mahesh Basyal, BSc¹^*, Li Li, M.D.¹^*, Takahiko Seki, PhD³^*, Arnaud Lesegretain⁴^*, Naval Daver, MD⁵ and Michael Andreeff, MD, PhD^1,6

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, MD Anderson Cancer Center, Houston, TX
³Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, JPN
⁴Daiichi Sankyo, Inc, Basking Ridge, NJ
⁵MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

5:30 PM

947

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Troy Robinson, BS^1,2, Robert L. Bowman, PhD^2,3, Sonali Persaud, BS²^*, Ying Liu, MD, PhD^4,5^*, Qi Gao, MLS⁶^*, Jing-Ping Zhang, PhD⁷^*, Xiaotian Sun, PhD⁶^*, Adam Sciambi, PhD⁸^*, Aaron Llanso⁹^*, Christopher Famulare, MS¹⁰^*, Aaron D Goldberg, MD, PhD¹¹, Ahmet Dogan, MD, PhD⁶, Mikhail Roshal, MD⁶, Ross L. Levine, MD^2,12,13 and Wenbin Xiao, MD, PhD^2,6,10

¹Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY
²Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
³Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering, New York, NY
⁵Department of Pathology and Laboratory Medicine, Molecular Diagnostic Service, Memorial Sloan Kettering, New York, NY
⁶Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Mission Bio, Inc., South San Francisco, CA
⁹Mission Bio, South San Francisco, CA
¹⁰Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
¹²Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

5:45 PM

948

A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow

Hope L Mumme, BSc^1,2^*, Swati S Bhasin, PhD^1,2,3, Mariam Nawaz, BTech^3,4^*, Beena E Thomas, Ph.D^1,3^*, Chenbin Huang, BSc²^*, Deborah DeRyckere, BS, PhD^1,3, Sharon M. Castellino, MD, MSc^1,3, Daniel S. Wechsler, MD, PhD^1,3, Sunil S. Raikar, MD^1,3, Christopher C. Porter, MD^1,3, Douglas K Graham, MD, PhD^1,3 and Manoj Bhasin, PhD^1,2,3,5

¹Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
²Department of Biomedical Informatics, Emory University, Atlanta, GA
³Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
⁴School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA
⁵Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

617.O3.3 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations